Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ignace Vergote

Showing results (171-180 of 578) with videos related to

Pageof 58
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 20, 2015
Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumorStefanie Schrauwen, Lieve Coenegrachts, Jeroen Depreeuw, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 9, 2010
The use of lymph vessel markers to predict endometrial cancer outcomeIngrid Vandenput, Thomas Vanhove, Ben Van Calster, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2012
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal massesToon Van Gorp, Joan Veldman, Ben Van Calster, et al.
Human Mutation|October 6, 2009
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathwaysKarin Leunen, Olivier Gevaert, Anneleen Daemen, et al.
International Journal of Cancer|April 19, 2006
Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practiceOlivier Gevaert, Nathalie Pochet, Frank De Smet, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2009
Management of recurrent endometrioid endometrial carcinoma: an overviewF H van Wijk, M E L van der Burg, Curt W Burger, et al.
Breast Care (Basel, Switzerland)|September 9, 2010
Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian TumorJoachim Van Keirsbilck, Ine Riphagen, Hans Struyven, et al.
Medical Oncology (Northwood, London, England)|November 5, 2014
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS studyKlaus Pietzner, Ignace Vergote, Armando Santoro, et al.
Lymphatic Research and Biology|February 8, 2014
Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedemaNele Devoogdt, Steven Pans, An De Groef, et al.
Frontiers in Immunology|June 20, 2019
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian CancerThaïs Baert, Ann Vankerckhoven, Matteo Riva, et al.
Pageof 58

Showing results (171-180 of 578) with videos related to

Sort By:
Pageof 58
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 20, 2015
Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumorStefanie Schrauwen, Lieve Coenegrachts, Jeroen Depreeuw, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 9, 2010
The use of lymph vessel markers to predict endometrial cancer outcomeIngrid Vandenput, Thomas Vanhove, Ben Van Calster, et al.
European Journal of Cancer (Oxford, England : 1990)|January 10, 2012
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal massesToon Van Gorp, Joan Veldman, Ben Van Calster, et al.
Human Mutation|October 6, 2009
Recurrent copy number alterations in BRCA1-mutated ovarian tumors alter biological pathwaysKarin Leunen, Olivier Gevaert, Anneleen Daemen, et al.
International Journal of Cancer|April 19, 2006
Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practiceOlivier Gevaert, Nathalie Pochet, Frank De Smet, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 2, 2009
Management of recurrent endometrioid endometrial carcinoma: an overviewF H van Wijk, M E L van der Burg, Curt W Burger, et al.
Breast Care (Basel, Switzerland)|September 9, 2010
Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian TumorJoachim Van Keirsbilck, Ine Riphagen, Hans Struyven, et al.
Medical Oncology (Northwood, London, England)|November 5, 2014
Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS studyKlaus Pietzner, Ignace Vergote, Armando Santoro, et al.
Lymphatic Research and Biology|February 8, 2014
Postoperative evolution of thickness and echogenicity of cutis and subcutis of patients with and without breast cancer-related lymphedemaNele Devoogdt, Steven Pans, An De Groef, et al.
Frontiers in Immunology|June 20, 2019
Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian CancerThaïs Baert, Ann Vankerckhoven, Matteo Riva, et al.
Pageof 58